77 related articles for article (PubMed ID: 23431112)
1. Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study.
An G; Liu W; Katz DA; Marek G; Awni W; Dutta S
Drug Metab Dispos; 2013 May; 41(5):1035-45. PubMed ID: 23431112
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens.
An G; Liu W; Katz DA; Marek GJ; Awni W; Dutta S
Biopharm Drug Dispos; 2014 Oct; 35(7):417-29. PubMed ID: 25041811
[TBL] [Abstract][Full Text] [Related]
3. Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.
Katz DA; Liu W; Locke C; Jacobson P; Barnes DM; Basu R; An G; Rieser MJ; Daszkowski D; Groves F; Heneghan G; Shah A; Gevorkyan H; Jhee SS; Ereshefsky L; Marek GJ
Transl Psychiatry; 2013 Aug; 3(8):e295. PubMed ID: 23982627
[TBL] [Abstract][Full Text] [Related]
4. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
[TBL] [Abstract][Full Text] [Related]
7. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
[TBL] [Abstract][Full Text] [Related]
8. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Rohde JJ; Pliushchev MA; Sorensen BK; Wodka D; Shuai Q; Wang J; Fung S; Monzon KM; Chiou WJ; Pan L; Deng X; Chovan LE; Ramaiya A; Mullally M; Henry RF; Stolarik DF; Imade HM; Marsh KC; Beno DW; Fey TA; Droz BA; Brune ME; Camp HS; Sham HL; Frevert EU; Jacobson PB; Link JT
J Med Chem; 2007 Jan; 50(1):149-64. PubMed ID: 17201418
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
10. Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly Adults.
Liu W; Katz DA; Locke C; Daszkowski D; Wang Y; Rieser MJ; Awni W; Marek GJ; Dutta S
Clin Pharmacol Drug Dev; 2013 Apr; 2(2):133-51. PubMed ID: 27121668
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Soo GW; Law JH; Kan E; Tan SY; Lim WY; Chay G; Bukhari NI; Segarra I
Anticancer Drugs; 2010 Aug; 21(7):695-703. PubMed ID: 20629201
[TBL] [Abstract][Full Text] [Related]
12. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and 11β hydroxysteroid dehydrogenase 1 inhibition of thiazolidine derivatives with an adamantyl group.
Kwon SW; Kang SK; Lee JH; Bok JH; Kim CH; Dal Rhee S; Jung WH; Kim HY; Bae MA; Song JS; Ha DC; Cheon HG; Kim KY; Ahn JH
Bioorg Med Chem Lett; 2011 Jan; 21(1):435-9. PubMed ID: 21093259
[TBL] [Abstract][Full Text] [Related]
14. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
[TBL] [Abstract][Full Text] [Related]
15. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
16. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.
Herman BD; Fleishaker JC; Brown MT
Clin Pharmacol Ther; 1999 Oct; 66(4):374-9. PubMed ID: 10546921
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration.
Seidegård J
Clin Pharmacol Ther; 2000 Jul; 68(1):13-7. PubMed ID: 10945311
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.
An G; Liu W; Dutta S
J Clin Pharmacol; 2015 Oct; 55(10):1079-85. PubMed ID: 25931139
[TBL] [Abstract][Full Text] [Related]
19. Blood concentrations of everolimus are markedly increased by ketoconazole.
Kovarik JM; Beyer D; Bizot MN; Jiang Q; Shenouda M; Schmouder RL
J Clin Pharmacol; 2005 May; 45(5):514-8. PubMed ID: 15831774
[TBL] [Abstract][Full Text] [Related]
20. Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.
Sorensen B; Winn M; Rohde J; Shuai Q; Wang J; Fung S; Monzon K; Chiou W; Stolarik D; Imade H; Pan L; Deng X; Chovan L; Longenecker K; Judge R; Qin W; Brune M; Camp H; Frevert EU; Jacobson P; Link JT
Bioorg Med Chem Lett; 2007 Jan; 17(2):527-32. PubMed ID: 17070044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
